Advanced Biomed (ADVB) Liabilities and Shareholders Equity (2024 - 2026)

Advanced Biomed (ADVB) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $10.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 28.46% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 140.31% YoY) and the FY2025 annual result came in at $13.7 million, up 207.56% from the prior year.
• Liabilities and Shareholders Equity declined to $10.6 million in Q1 2026 per ADVB's latest filing, from $10.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $13.7 million in Q2 2025, with the low at $4.5 million in Q2 2024.
• Average Liabilities and Shareholders Equity over 3 years is $8.4 million, with a median of $8.3 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity surged 207.56% in 2025 and grew 28.46% in 2026.
• Advanced Biomed's Liabilities and Shareholders Equity stood at $4.5 million in 2024, then jumped by 140.9% to $10.9 million in 2025, then slipped by 1.88% to $10.6 million in 2026.
• Business Quant data shows ADVB's Liabilities and Shareholders Equity at $10.6 million in Q1 2026, $10.9 million in Q4 2025, and $6.2 million in Q3 2025.